StreetAlpha.app
Home › Stocks › TLSA

Tiziana Life Sciences Ltd (TLSA)

$0.62
▼ −8.14%
LAST CLOSE · NOV 20

Tiziana Life Sciences develops antibody therapies for neurodegenerative and neuroinflammatory diseases from its base in London. It last closed at $0.62 on Nov 20, down 8.14% on the day. Over the last 12 months TLSA insiders bought $986K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is TLSA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TLSA.

Key Stats

Fiscal 2024
Results
Net income
−$11.9M
Free cash flow
−$1.5M
Balance sheet
Cash & equivalents
$3.7M
At Dec 31
Shareholder equity
$3.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2020: −$26.1M−$26.1MFY2020FY2021: −$23.4M−$23.4MFY2021FY2022: −$15.4M−$15.4MFY2022FY2023: −$17.7M−$17.7MFY2023FY2024: −$11.9M−$11.9MFY2024

From TLSA's SEC filings, latest 20-F for the period ending Dec 31, 2024 (filed May 1). Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TLSA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TLSA

Technical Analysis

TLSA · as of the Nov 20 close · updated each morning
Downtrend

The stock is 14% below its 20 day and 44% below its 50 day average. It is 85% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot S1 at $0.59, and the nearest resistance the Pivot at $0.64.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 15.3%/day
Key levels
$1.9052 week high+206.5%
$1.15200 day average+85.5%
$1.01Swing high (Sep 17)+62.9%
$0.98100 day average+58.1%
$0.8950 day average+43.5%
$0.7120 day average+14.5%
$0.68Pivot R1+9.7%
$0.64Pivot+3.2%
$0.62Last close
$0.59Pivot S1−4.8%
$0.57Swing low (Nov 5)−8.1%
$0.5552 week low−11.3%
Indicators
RSI (14)40.35Middle of its rangeNeutral
MACD-0.08Above its signal lineBullish
Stochastic45.2Middle of its rangeNeutral
ADX (14)30.2Trending down
Williams %R-75.7Oversold below −80, overbought above −20Neutral
CCI (20)-51.1Oversold below −100, overbought above 100Neutral
Rate of change−9.9%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 15.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TLSA

What happened before

See how TLSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TLSA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TLSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TLSAHow many large options trades hit TLSA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TLSA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲16 buying vs 12 selling
  • ▲Shares held by funds +65.0%
  • ▲Funds holding +4
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding3632+12.5%
In funds' top 1000–
Held by funds–––
New / increased7 / 96 / 7+23.1%
Reduced / sold out9 / 34 / 7+9.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TLSA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TLSA Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$986K2 buys · 1 insider
Sold$00 sales · 0 insiders
2026-08 bought $986KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 5Ivor ElrifiCEOBuy321,423$0.99$319K
Aug 3Ivor ElrifiCEOBuy667,000$1.00$667K
Every insider buy and sale for TLSA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TLSA insider trades →

From SEC Form 4 filings by TLSA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TLSA is in one of them and how their past TLSA trades turned out.

TLSA in the AI portfolios
Loading…

TLSA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TLSA in an article yet. Here's the latest on the wider market.

TLSA in the news

About Tiziana Life Sciences

Tiziana Life Sciences is a biotechnology company based in London, England, that develops treatments for neurodegenerative and neuroinflammatory diseases. Its main candidate, Foralumab, is an antibody being tested as a nasal treatment for conditions such as secondary progressive multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. The company is focused on these clinical programs and aims its work at patients with these conditions.

Headquarters
London, England, United Kingdom